514 related articles for article (PubMed ID: 19352662)
21. Phase I study of fotemustine in pediatric patients with refractory brain tumors.
Hargrave DR; Bouffet E; Gammon J; Tariq N; Grant RM; Baruchel S
Cancer; 2002 Sep; 95(6):1294-301. PubMed ID: 12216098
[TBL] [Abstract][Full Text] [Related]
22. Accelerated radiotherapy regimen for malignant gliomas using stereotactic concomitant boosts for dose escalation.
Cardinale RM; Schmidt-Ullrich RK; Benedict SH; Zwicker RD; Han DC; Broaddus WC
Radiat Oncol Investig; 1998; 6(4):175-81. PubMed ID: 9727877
[TBL] [Abstract][Full Text] [Related]
23. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study.
Korones DN; Fisher PG; Kretschmar C; Zhou T; Chen Z; Kepner J; Freeman C
Pediatr Blood Cancer; 2008 Feb; 50(2):227-30. PubMed ID: 17278121
[TBL] [Abstract][Full Text] [Related]
24. Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas.
Minniti G; Agolli L; Falco T; Scaringi C; Lanzetta G; Caporello P; Osti MF; Esposito V; Enrici RM
J Neurooncol; 2015 May; 122(3):559-66. PubMed ID: 25702193
[TBL] [Abstract][Full Text] [Related]
25. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
Scoccianti S; Detti B; Sardaro A; Iannalfi A; Meattini I; Leonulli BG; Borghesi S; Martinelli F; Bordi L; Ammannati F; Biti G
Anticancer Drugs; 2008 Jul; 19(6):613-20. PubMed ID: 18525321
[TBL] [Abstract][Full Text] [Related]
26. Logistic regression model of fotemustine toxicity combining independent phase II studies.
Raymond E; Haon C; Boaziz C; Coste M
Cancer; 1996 Nov; 78(9):1980-7. PubMed ID: 8909320
[TBL] [Abstract][Full Text] [Related]
27. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.
Yung WK; Kyritsis AP; Gleason MJ; Levin VA
Clin Cancer Res; 1996 Dec; 2(12):1931-5. PubMed ID: 9816151
[TBL] [Abstract][Full Text] [Related]
28. A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas.
Packer RJ; Krailo M; Mehta M; Warren K; Allen J; Jakacki R; Villablanca JG; Chiba A; Reaman G
Cancer; 2005 Nov; 104(9):1968-74. PubMed ID: 16177987
[TBL] [Abstract][Full Text] [Related]
29. [Fotemustine: a pilot phase II trial in sarcoma of the soft tissues].
Spielmann M; Berille J; Khayat D; Bizzari JP; Jacquillat C; Tursz T
Bull Cancer; 1991; 78(5):453-6. PubMed ID: 1878607
[TBL] [Abstract][Full Text] [Related]
30. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Fukushima T; Yamamoto M; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
Anticancer Res; 1998; 18(5D):3965-70. PubMed ID: 9854511
[TBL] [Abstract][Full Text] [Related]
31. [Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].
Afra D; Sipos L; Vitanovics D
Ideggyogy Sz; 2002 Jan; 55(1-2):38-44. PubMed ID: 12122942
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of supratentorial glioma in adults by intra-arterial HECNU. Experience of the Pitié-Salpétrière group].
Poisson M; Chiras J; Fauchon F; Delattre JY
Rev Neurol (Paris); 1992; 148(6-7):441-7. PubMed ID: 1448664
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.
Voelter V; Schalenbourg A; Pampallona S; Peters S; Halkic N; Denys A; Goitein G; Zografos L; Leyvraz S
Melanoma Res; 2008 Jun; 18(3):220-4. PubMed ID: 18477897
[TBL] [Abstract][Full Text] [Related]
35. [Significance of stereotactic biopsy for the management of WHO grade II supratentorial glioma].
Muacevic A; Kreth FW
Nervenarzt; 2003 Apr; 74(4):350-4. PubMed ID: 12707704
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcome of high-precision radiotherapy in patients with brain stem gliomas: results from a difficult-to-treat patient population using fractionated stereotactic radiotherapy.
Combs SE; Steck I; Schulz-Ertner D; Welzel T; Kulozik AE; Behnisch W; Huber PE; Debus J
Radiother Oncol; 2009 Apr; 91(1):60-6. PubMed ID: 19285356
[TBL] [Abstract][Full Text] [Related]
37. Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme.
De Felice F; Bulzonetti N; Musio D; D'Elia A; Salvati M; Tombolini V
Anticancer Res; 2013 Sep; 33(9):4013-6. PubMed ID: 24023343
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WK
J Clin Oncol; 2000 Feb; 18(4):708-15. PubMed ID: 10673511
[TBL] [Abstract][Full Text] [Related]
39. [Clinical results of supratentorial astrocytoma grade II].
Matsumoto K; Abe T; Terada K; Tabuchi A; Adachi Y; Mizumatsu S; Ono Y; Tamiya T; Ohmoto T; Furuta T
No Shinkei Geka; 1999 Feb; 27(2):139-45. PubMed ID: 10065446
[TBL] [Abstract][Full Text] [Related]
40. Concurrent chemoradiotherapy with weekly paclitaxel in malignant cerebral glioma treatment.
Montemor JP; Peria FM; Monti CR; Petrilli LS; Colli BO; Carlotti Júnior CG
Onkologie; 2008 Sep; 31(8-9):435-9. PubMed ID: 18787350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
